European Union - English - EMA (European Medicines Agency)

schering-plough europe - posaconazole - candidiasis; mycoses; coccidioidomycosis; aspergillosis - antimycotics for systemic use - posaconazole sp is indicated for use in the treatment of the following fungal infections in adults (see section 5.1):- invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products;- fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b;- chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- coccidioidomycosis in patients with disease that is refractory to amphotericin b, itraconazole or fluconazole or in patients who are intolerant of these medicinal products;- oropharyngeal candidiasis: as first-line therapy in patients who have severe disease or are immunocompromised, in whom response to topical therapy is expected to be poor.refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.posaconazole sp is also indicated for prophylaxis of invasive fungal infections in the following patients:- patients receiving remission-induction chemotherapy for acute myelogenous leukemia (aml) or myelodysplastic syndromes (mds) expected to result in prolonged neutropenia and who areat high risk of developing invasive fungal infections;- hematopoietic stem cell transplant (hsct) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

holcus lanatus) pollen 50hep/ml solution for skin prick test (inmunotek - yorkshire fog (velvet grass, holcus lanatus) pollen allergen extract - solution for skin-prick test

Ireland - English - HPRA (Health Products Regulatory Authority)

shire pharmaceutical contracts ltd - lisdexamfetamine dimesylate - capsules hard - 20 milligram - phenylethylamine derivatives - centrally acting sympathomimetics - it is indicated as part of a comprehensive treatment programme for attention deficit/hyperactivity disorder (adhd) in children aged 6 years and over when response to previous methylphenidate treatment is considered clinically inadequate

Ireland - English - HPRA (Health Products Regulatory Authority)

shire pharmaceutical contracts ltd - lisdexamfetamine dimesylate - capsules hard - 40 milligram - phenylethylamine derivatives - centrally acting sympathomimetics - it is indicated as part of a comprehensive treatment programme for attention deficit/hyperactivity disorder (adhd) in children aged 6 years and over when response to previous methylphenidate treatment is considered clinically inadequate

Ireland - English - HPRA (Health Products Regulatory Authority)

shire pharmaceutical contracts ltd - lisdexamfetamine dimesylate - capsules hard - 60 milligram - phenylethylamine derivatives - centrally acting sympathomimetics - it is indicated as part of a comprehensive treatment programme for attention deficit/hyperactivity disorder (adhd) in children aged 6 years and over when response to previous methylphenidate treatment is considered clinically inadequate.

Malta - English - Medicines Authority

strides arcolab international limited unit 4, metro centre, tolpits lane, watford, hertfordshire, wd 189 ss, united kingdom - cytarabine - solution for infusion or injection - cytarabine 20 mg/ml - antineoplastic agents

Malta - English - Medicines Authority

strides arcolab international limited unit 4, metro centre, tolpits lane, watford, hertfordshire, wd 189 ss, united kingdom - cytarabine - solution for infusion or injection - cytarabine 20 mg/ml - antineoplastic agents

Malta - English - Medicines Authority

strides arcolab international limited unit 4, metro centre, tolpits lane, watford, hertfordshire, wd 189 ss, united kingdom - cytarabine - solution for infusion or injection - cytarabine 20 mg/ml - antineoplastic agents

Malta - English - Medicines Authority

strides arcolab international limited unit 4, metro centre, tolpits lane, watford, hertfordshire, wd 189 ss, united kingdom - cytarabine - solution for infusion or injection - cytarabine 100 mg/ml - antineoplastic agents

Malta - English - Medicines Authority

strides arcolab international limited unit 4, metro centre, tolpits lane, watford, hertfordshire, wd 189 ss, united kingdom - docetaxel - concentrate and solvent for solution for infusion - docetaxel 40 mg - antineoplastic agents